Research groups
Websites
-
Fulga Lab
Research group
-
MRC Weatherall Institute of Molecular Medicine
Research Institute
Tudor Fulga
Visiting Professor of Genome Biology
I am now part of Vertex Pharmaceuticals as Vice President/Head of Gene Editing and Discovery Biology, but I remain associated with the MRC WIMM until October 2021 in the first instance, continuing with my existing collaborations and mentoring my existing graduate students.
My group is focused on creating synthetic systems capable of rewiring or enhancing naturally-evolved cellular behaviours, and applying the underlying concepts to advance the scope of cell engineering approaches for basic research and therapeutic applications. This scientific program is inspired by advances in miRNA biology, synthetic biology and genome engineering, and supported by an interdisciplinary research infrastructure and key strategic collaborations.
I obtained my PhD from the European Molecular Biology Laboratory (EMBL) in Heidelberg, and subsequently received training at Harvard Medical School, first as a postdoctoral fellow and later as an Instructor in Cell Biology. As a graduate student, I initially studied the process of protein translocation across the ER with Irmgard Sinning, and later the cellular events controlling invasive cell migration with Pernille Rorth. I later joined the laboratory of Mel Feany at Harvard Medical School as a postdoctoral fellow, where I investigated the molecular mechanisms underlying neurodegeneration in Alzheimer’s disease. Subsequently, I was appointed Instructor in Cell Biology at Harvard Medical School and together with my advisor David Van Vactor I pioneered a highly versatile in vivo transgenic technology for conditional knockdown of miRNAs. In 2011/2012, I joined the Weatherall Institute of Molecular Medicine (WIMM) in Oxford as a Group Leader and MRC senior research fellow. In 2014 I was appointed Associate Professor of Genome Biology at Radcliffe Department of Medicine, University of Oxford.
Key publications
-
Decoupling tRNA promoter and processing activities enables specific Pol-II Cas9 guide RNA expression.
Journal article
Knapp DJHF. et al, (2019), Nat Commun, 10
-
Precise tuning of gene expression levels in mammalian cells.
Journal article
Michaels YS. et al, (2019), Nat Commun, 10
-
In situ functional dissection of RNA cis-regulatory elements by multiplex CRISPR-Cas9 genome engineering.
Journal article
Wu Q. et al, (2017), Nat Commun, 8
-
A multiplexable TALE-based binary expression system for in vivo cellular interaction studies.
Journal article
Toegel M. et al, (2017), Nat Commun, 8
-
Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors.
Journal article
Baeumler TA. et al, (2017), Cell Rep, 20, 2639 - 2653
-
Rational design of inducible CRISPR guide RNAs for de novo assembly of transcriptional programs.
Journal article
Ferry QRV. et al, (2017), Nat Commun, 8
-
A transgenic resource for conditional competitive inhibition of conserved Drosophila microRNAs.
Journal article
Fulga TA. et al, (2015), Nat Commun, 6
-
Understanding functional miRNA-target interactions in vivo by site-specific genome engineering.
Journal article
Bassett AR. et al, (2014), Nat Commun, 5
-
Cross-talking noncoding RNAs contribute to cell-specific neurodegeneration in SCA7.
Journal article
Tan JY. et al, (2014), Nat Struct Mol Biol, 21, 955 - 961
-
Transgenic microRNA inhibition with spatiotemporal specificity in intact organisms.
Journal article
Loya CM. et al, (2009), Nat Methods, 6, 897 - 903
-
Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo.
Journal article
Fulga TA. et al, (2007), Nat Cell Biol, 9, 139 - 148
Recent publications
-
Addendum: Precise tuning of gene expression levels in mammalian cells.
Journal article
Michaels YS. et al, (2019), Nat Commun, 10
-
Decoupling tRNA promoter and processing activities enables specific Pol-II Cas9 guide RNA expression.
Journal article
Knapp DJHF. et al, (2019), Nat Commun, 10
-
Precise tuning of gene expression levels in mammalian cells.
Journal article
Michaels YS. et al, (2019), Nat Commun, 10
-
CRISPR-Cas9 targeting of MMP13 in human chondrocytes leads to significantly reduced levels of the metalloproteinase and enhanced type II collagen accumulation.
Journal article
Seidl CI. et al, (2019), Osteoarthritis Cartilage, 27, 140 - 147
-
MicroRNAs Regulate Sleep and Sleep Homeostasis in Drosophila.
Journal article
Goodwin PR. et al, (2018), Cell Rep, 23, 3776 - 3786